WASHINGTON — Robert Califf, President Biden’s choice to lead the Food and Drug Administration, earned $2.7 million as an executive at Google’s life science arm Verily, and he holds between $1 million and $5 million in equity in the company, according to a recent financial statement filed with the White House.
Califf is also coming into the FDA’s top job with a massive stock portfolio. His financial statement lists roughly 30 companies in which he owns more than $100,000 worth of stock as part of a retirement account. His holdings include between $250,000 and $500,000 worth of stock in the pharmaceutical giants Bristol Myers Squibb and Amgen and between $100,000 and $250,000 in Gilead.
Biden’s FDA nominee also has large stakes in two biotech companies, Cytokinetics and Centessa Pharmaceuticals. Califf holds vested stock options worth between $800,000 and $1.9 million in the former, which is developing drugs for heart failure and ALS. He also holds between $1 million and $5 million in unvested stock options in Centessa, the drug company launched by the former head of Operation Warp Speed, Moncef Slaoui. Califf currently sits on the board of directors for both.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
